Immuron achieves record Travelan® sales
13 févr. 2024 06h00 HE
|
Immuron Limited
Highlights: Travelan® sales YTD Jan 2024 of $2.7 million exceed peak full year FY20 sales of $2.5 millionAustralian Travelan® YTD Jan 2024 sales $2.1 millionUSA Travelan® YTD Jan 2024 sales $0.6...
Immuron CEO, Steven Lydeamore Investor Webinar Presentation
08 févr. 2024 06h00 HE
|
Immuron Limited
MELBOURNE, Australia, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Chief...
Immuron achieves record half yearly Travelan® sales
16 janv. 2024 06h00 HE
|
Immuron Limited
Highlights: Record half yearly Travelan® sales of $2,334,969Total sales of A$2,355,580 in H1, FY24 $1,771,932 increase on H1, FY23 sales51% higher than pre-pandemic period H1, FY20 sales ...
Immuron Clinical Trials Update
22 déc. 2023 06h00 HE
|
Immuron Limited
Highlights: US Naval Medical Research Command (NMRC) campylobacter clinical program completes in-patient phase Manufacture of IMM-529 drug substance to support the Pre-IND information package has...
Immuron Announces First Patients Enrolled in Campylobacter Challenge Clinical Study
04 déc. 2023 06h00 HE
|
Immuron Limited
Highlights: First participants enrolled in the US Naval Medical Research Command Clinical Trial Clinical Study initiated to evaluate the efficacy of a new Immuron clinical product to protecting...
Immuron CEO, Steven Lydeamore Investor Webinar Presentation
28 nov. 2023 06h33 HE
|
Immuron Limited
MELBOURNE, Australia, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to invite...
Immuron CEO Steven Lydeamore Investor Webinar Presentation
13 nov. 2023 18h00 HE
|
Immuron Limited
MELBOURNE, Australia, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to invite...
Immuron CEO Steven Lydeamore presented at AusBioInvest
30 oct. 2023 07h21 HE
|
Immuron Limited
MELBOURNE, Australia, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, is pleased to advise our...
Immuron Announces Travelan® Clinical Study Cohort 2 commences
18 oct. 2023 06h00 HE
|
Immuron Limited
Highlights: Second cohort of 34 healthy volunteers enrolled in the Travelan® Clinical Trial Clinical Trial to examine a dosing regimen for Travelan® more suited to the US military has commenced...
Immuron achieves record quarterly Travelan® sales
11 oct. 2023 06h00 HE
|
Immuron Limited
Highlights: Record quarterly Travelan® sales of $1,550,240Total sales of A$1,565,767 in Q1, FY24 $1,508,933 increase on Q1, FY23 sales130% higher than pre-pandemic period Q1, FY20 sales ...